Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 9/25/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. David J. Glass

Wrong Dr. David J. Glass?

Executive Director, Muscle Diseas...

Phone: (617) ***-****  
Email: d***@***.com
Novartis Institutes for BioMedical Research Inc
250 Massachusetts Avenue
Cambridge , Massachusetts 02139
United States

Company Description: The Novartis Institutes for BioMedical Research, based in Cambridge, Mass., will focus on disease areas with significant new opportunities, according to the...   more

Employment History

Board Memberships and Affiliations


  • MD
    New York Medical College
  • undergraduate degree
    Columbia University
  • M.D.
    New York Medical College
61 Total References
Web References
Biomarkers & Medical Diagnostics | Leaders in Pharmaceutical Business Intelligence, 25 Sept 2015 [cached]
According to Jocelyn Kaiser, writing at the Science web site, David Glass, who works at the Novartis Institutes for Biomedical Research in Cambridge, Massachusetts, and his colleagues have made use of an antibody that specifically binds to GDF11 to detect the protein and measure its concentration in the blood and tissues.
Urban Debate Leagues > Who We Are > Our Board, 16 Sept 2015 [cached]
David Glass Global Head, Muscle Diseases Novartis Institutes for Biomedical Research
SMA Foundation | Scientific Advisory Board, 14 June 2012 [cached]
David J. Glass, MD
Dr. David J. Glass has been the Global Head of Muscle Diseases research at Novartis Institutes for Biomedical Research since 2005. A native of New York, Dr. Glass received his undergraduate degree from Columbia University and his MD from New York Medical College. After postdoctoral work at Columbia, he worked at Regeneron Pharmaceuticals for 14 years before establishing the Muscle Diseases group at Novartis.
Dr. Glass's research has led to several key scientific findings in the area of skeletal muscle atrophy and hypertrophy. He is the co-author of more than 60 peer-reviewed articles on cell signaling mechanisms in neuromuscular disease, obesity, and cancer.
Dr. Glass is an elected member of the American Society for Biochemistry and Molecular Biology and the American Society for Clinical Investigation. He is also a Visiting Scientist at Harvard Medical School, where he teaches a course on experimental design. His book, Experimental Design for the Practicing Biologist, was well-reviewed and, in addition, he co-authored a paper that appeared in the "Leading Edge" section of the journal Cell on the philosophy of science, advocating the use of questions as opposed to hypotheses in framing experimental projects.
For GDF11, "You could imagine that ... [cached]
For GDF11, "You could imagine that when it came out last year that it helped muscle, it was quite a surprise," says David Glass, executive director of the muscle diseases group at the Novartis Institutes for Biomedical Research in Cambridge, Massachusetts. "Did we miss something?"
Glass and his colleagues set out to determine why GDF11 had this apparent effect. First, they tested the antibodies and other reagents that Wagers' group had used to measure GDF11 levels, and found that these chemicals could not distinguish between myostatin and GDF11. When the Novartis team used a more specific reagent to measure GDF11 levels in the blood of both rats and humans, they found that GDF11 levels actually increased with age - just as levels of myostatin do. That contradicts what Wagers' group had found.
Glass's team next used a combination of chemicals to injure a mouse's skeletal muscles, and then regularly injected the animal with three times as much GDF11 as Wagers and her team had used.
Rather than regenerating the muscle, Glass found, GDF11 seemed to make the damage worse by inhibiting the muscles' ability to repair themselves. He and his colleagues report their results on 19 May in Cell Metabolism4.
Glass says that although his group's results do not explain why parabiosis works, they could help to explain the mechanism behind bimagrumab, an experimental Novartis treatment for muscle weakness and wasting. The drug, which is currently in clinical trials, blocks myostatin - and perhaps GDF11 as well.
Meticulous methods
Thomas Rando, a stem-cell biologist at Stanford University in California, praises the attention to detail in the methods used by Glass and his team.
Wagers' team in Harvard really did some pioneer work in this space, and Glass and his team in Novartis made further study and got some contradictory findings.
The FSH Society Board of Directors, 25 Dec 2014 [cached]
David J. Glass, M.D.
David J. Glass, M.D. Dr. Glass is Global Head, Muscle Diseases for Novartis Institutes for Biomedical Research, Cambridge, Massachusetts. Prior to joining Novartis, he was Vice President for Muscle Diseases at Regeneron Pharmaceuticals, where he worked for 14 years. He holds an M.D. from New York Medical College and conducted postdoctoral work at Columbia University. He is the co-author of more than 50 peer-reviewed research articles on cell signaling mechanisms in neuromuscular disease, obesity, and cancer.
Michelle and her husband, David, have two daughters.
Other People with the name "Glass":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.